Oncternal Therapeutics
1042-B North El Camino Real
Encinitas, CA 92024
Encinitas, CA 92024
Encinitas, CA 92024
United States
Tel: 858-434-1113
Fax: 858-408-3010
Website: http://www.oncternal.com/
Email: info@oncternal.com
152 articles about Oncternal Therapeutics
-
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5/20/2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,943,636 shares of its common stock, at a purchase price of $2.5725 per share, in a registered direct offering priced at-the-market under Nasd
-
Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
5/19/2020
58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 months Cirmtuzumab continued to be well tolerated in this trial SAN DIEGO--( BUSINESS WIRE )-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel
-
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
5/7/2020
Management to host webcast today at 3:00 pm ET Oncternal Therapeutics, Inc. reporting first quarter 2020 financial results
-
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
5/1/2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results after the U.S. financial markets close on Thursday, May 7, 2020. Oncternal’s management will host a webcast and conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Company’s financial results and provide
-
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
3/16/2020
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported fourth quarter and full year 2019 financial results.
-
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
3/11/2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019 financial results on March 16, 2020.
-
Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
3/11/2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib, in patients with relapsed/refractory mantle cell lymphoma (MCL) as part of the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial
-
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
2/6/2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of preclinical data from its ROR1 chimeric antigen receptor T cell (CAR-T) program at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) meeting in Orlando, Florida.
-
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium
12/12/2019
Four of seven evaluable patients with HER2-negative, metastatic or locally-advanced unresectable breast cancer achieved a partial response for an objective response rate of 57%
-
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma
12/11/2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for enrollment a Phase 1b expansion cohort of its ongoing clinical trial evaluating TK216, a first-in-class, targeted, investigational small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma.
-
Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting
12/9/2019
Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100%
-
Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium
12/3/2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical conferences.
-
Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference
11/21/2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st Annual Healthcare Conference in New York City on Thursday, December 5, 2019 at 11:50 a.m. ET / 8:50 a.m. PT.
-
Clinical Catch-Up: November 11-15
11/18/2019
It was a busy week for clinical trial announcements. Here’s a look. -
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
11/14/2019
Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated
-
Oncternal Therapeutics to Present at Stifel Healthcare Conference
11/11/2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.
-
Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
11/7/2019
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced financial results for the third quarter ended September 30, 2019, and provided a business update.
-
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
11/5/2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted small molecule inhibitor of ETS transcription factor oncoproteins – will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting in Tokyo, Japan, on November 16, 2019.
-
Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update
10/31/2019
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019.
-
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
10/3/2019
Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma